HeartWare International — Technical Presentation (April 2011)
19 slides from HeartWare International's technical presentation, Apr 18, 2011
Slide 1: Evaluation of the HeartWare HVAD LVAS: ADVANCE BTT Trial Results and Continued Access Update
Evaluation of the HeartWare HVAD Left Ventricular Assist System for the Treatment of Advanced Heart Failure: Results of the ADVANCE Bridge to Transplant Trial and Update with Continued Access Patients M Slaughter, K Aaronson, S Boyce, LW Miller, EC McGee, WG Cotts, M Acker, ML Jessup, ID Gregoric, P
Slide 2: HeartWare Ventricular Assist System
HeartWare Ventricular Assist System HVAD miniaturized implantable blood pump Pericardial placement - no pump pocketProvides up to 10 L/min of flowCentrifugal design, continuous flowHybrid magnetic / hydrodynamic impeller suspensionOptimizes flow, pump surface washing, and hemocompatibilityThin (4.2
Slide 3: ADVANCE Trial Design
Multi-site (30), prospective trial to evaluate the HeartWare HVAD as a bridge-to-transplant in the USEnrollment period was August 2008 to February 2010 All patients were followed for ^ 180 days following implant or until cardiac transplantation, device explant for recovery or deathTreatment group wa
Slide 4: Recap of Results of the ADVANCE Trial
"Success" was 92% - survival to 180 days on original device or transplantSurvival at 180 days was 94% Non-inferiority to INTERMACS control was established (p < 0.0001) Recap of Results of the ADVANCE Trial
Slide 5: Continued Access Protocol for ADVANCE Trial
Continued Access Protocol for ADVANCE Trial Continued access for the bridge-to-transplant indication was approved for the 30 sites that enrolled at least 1 patient in ADVANCEThe same enrollment protocol is in effect for CAP 3 allotments of additional patients (54, 54 and 94) have been granted by the
Slide 6: CAP Enrollment
CAP Enrollment Actual CAP Enrollment to March 2011 3 2 g s 5 E 5 é © 9 a9 a9 a9 as aos asi aos ass as 99 PP 9 209 19 2 2M 29 a a9 a SPA eB se Gee OSH goth ge woh ceo™ ot
Slide 7: Baseline Characteristics
Baseline Characteristics ADVANCE (N = 140) CAP (N =110) Age (years) 53. 3 + 10.3 52 + 13.4 Male sex (%) 101 (72) 76 (66) Race [number (%)] White 102 (73) 76 (66) Black/African American 32 (23) 31 (27) Hispanic/Other 6 (3.3) 8 (7) Body-mass index (kg/m2) 28.6 + 6.1 28.8 + 6.2 Body surface area (m2) 2
Slide 8: Baseline Characteristics
Baseline Characteristics ADVANCE (N = 140) CAP (N = 110) Left ventricular ejection fraction (%) 17.8 + 7.1 17.5 + 7.4 Arterial blood pressure (mm Hg) Systolic 104 + 16 103 + 16 Diastolic 64 + 11 68 + 13 Mean 77 + 13 81 + 12 Pulmonary capillary wedge pressure (mm Hg) 23 + 9 23 + 8 Cardiac index (lite
Slide 9: INTERMACS Classification
INTERMACS Classification ADVANCEPatients (%) CAPPatients (%) INTERMACS 1 7 (5.0) 4 (4.0) INTERMACS 2 39 (27.9) 35 (34.7) INTERMACS 3 62 (44.3) 48 (47.5) INTERMACS 4-7 32 (22.3) 14 (12.7) CAP patients appear to have more advanced disease by INTERMACS criteria. 250 patients; 174 patient-years
Slide 10: Adverse Events
Adverse Events Events0-30 Days Events> 30 Days Event Rate* Event Rate* AHA† Bleeding requiring re-op 23 0 0.13 0.20 GI bleeding (22 patients; 8.8%) 11 28 0.22 0.23 Neurological events Ischemic CVA 12 6 0.10 0.10 Hemorrhagic CVA 3 5 0.05 0.06 TIA 2 7 0.05 0.09 Venous thrombosis 8 4 0.07 0.09 Arterial
Slide 11: Adverse Events
Adverse Events 250 patients; 174 patient-years Events0-30 Days Events> 30 Days Event Rate* Event Rate* AHA Infections Driveline exit 4 25 0.17 0.22 Sepsis 11 20 0.18 0.16 Respiratory dysfunction 38 19 0.33 0.45 Arrhythmia Ventricular 33 29 0.36 0.29† Supraventricular 42 4 0.26 - Right heart failure
Slide 12: Device Exchange
Device Exchange Reasons for ExchangeGraft Infection (1) BiVAD (1) Tissue in Connector (1) Iatrogenic (3) Thrombus (11) * 5 patients treated with LV tPA - not exchanged
Slide 13: Aspirin Showed Benefit Without Increased GI Bleeding or Hemorrhagic Stroke
325 mg Aspirin Showed Benefit Without Increased GI Bleeding or Hemorrhagic Stroke GI Bleeding or Hemorrhagic Stroke GI Bleeding or Hemorrhagic Stroke Mean INR 2.1
Slide 14: Strokes
Strokes Total Disabling† Rate (events PPY§) Hemorrhagic Strokes 8 6 (75%) 0.03 Ischemic Strokes 18 6 (33%) 0.03 † Defined as a Modified Rankin Score of > 4§ Disabling strokes, events/patient-year
Slide 15: Freedom from Major Infections
Freedom from Major Infections DrivelineSepsis 91% 89% 85% 90% 85% 81%
Slide 16: Survival for ADVANCE and CAP
Survival for ADVANCE and CAP CAPADVANCE (BTT) 98% 95% 92% 97% 94% 86% 98% 96%
Slide 17: Causes of Death for ADVANCE and CAP
Causes of Death for ADVANCE and CAP Causes Number of Patients Multisystem Organ Failure 10 Intracerebral Bleeding 4 Right Heart Failure 4 Undetermined 2 Respiratory Failure 1 Sepsis 1 Bone Marrow Suppression 1 Controller failure 1 TOTAL 24 N = 250 patients
Slide 18: Survival Post-Transplant
Survival Post-Transplant 95% 93% 93% N = 78 patients
Slide 19: Summary
Summary 250 patients have been enrolled in ADVANCE and CAP for 174 patient-years of support.Survival remains high in CAP, confirming ADVANCE results.Sepsis and driveline infections were notably infrequent. Full dose aspirin (325 mg) was associated with low risk of pump thrombus without increased ris
HeartWare International — Technical Presentation (April 2011) on 6ix